The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market Compare Between 2026 And 2030?
The anti-vascular endothelial growth factor therapeutics market size has experienced slight expansion in recent years. Its value is expected to increase from $12.17 billion in 2025 to $12.36 billion in 2026, showing a compound annual growth rate (CAGR) of 1.6%. This historical growth can be attributed to factors such as the approval of lucentis and eylea, the rising prevalence of age-related macular degeneration, the growing incidence of diabetic retinopathy, progress in molecular biology for angiogenesis inhibition, and the expansion of hospital ophthalmology services.
The anti-vascular endothelial growth factor therapeutics market size is anticipated to experience consistent expansion over the coming years. This market is projected to reach $13.59 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 2.4%. The increase during the forecast period can be attributed to the introduction of next-generation anti-VEGF therapeutics, enhanced investment in precision oncology, the expanding penetration of the biosimilar market, rising healthcare spending in emerging markets, and the adoption of combination therapies for retinal conditions. Significant trends expected during this period involve the growing acceptance of anti-VEGF therapies in ophthalmology, the development of targeted cancer therapies, the creation of biosimilar anti-VEGF drugs, an aging global population driving AMD treatments, and the proliferation of outpatient and specialty clinics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
Which Factors Are Influencing The Growth Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market is expected to witness growth propelled by the increasing prevalence of ophthalmic diseases. This prevalence refers to the number or proportion of individuals within a given population diagnosed with or exhibiting specific eye conditions or diseases. Anti-vascular endothelial growth factor (VEGF) therapeutics play a role in reducing the incidence of ophthalmic diseases by effectively treating conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For example, in August 2023, the World Health Organization, a Switzerland-based international public health organization, reported that globally, approximately 2.2 billion people experience near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Additionally, among these individuals, 88.4 million are affected by refractive error, 94 million have cataracts, 8 million have age-related macular degeneration, and around 3.9 million have diabetic retinopathy. Therefore, the rising prevalence of ophthalmic diseases is a key factor driving the expansion of the anti-vascular endothelial growth factor therapeutics market.
How Are Different Segments Classified In The Anti-Vascular Endothelial Growth Factor Therapeutics Market Segment Analysis?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Which Trends Are Guiding The Direction Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Key players in the anti-VEGF therapeutics market are increasingly forging strategic alliances to hasten the advancement, market launch, and integration of VEGF inhibitors. These joint ventures allow companies to utilize synergistic expertise, access cutting-edge technologies, and broaden their market footprint. To illustrate, in January 2025, Teva Pharmaceuticals International GmbH, a Swiss subsidiary of Teva Pharmaceutical Industries focused on biosimilars and complex generics, initiated a strategic partnership with Klinge Biopharma GmbH and Formycon AG. This collaboration aims to commercialize FYB203, a biosimilar candidate to Eylea (aflibercept), across Europe (excluding Italy) and Israel. Within this alliance, Teva utilizes its established commercial infrastructure and distribution network to reinforce its position in the anti-VEGF therapeutics market. Formycon AG assumes responsibility for the development of FYB203, and Klinge Biopharma GmbH possesses exclusive global commercialization rights for this product.
Who Are The Companies Driving Activity In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market are F. Hoffmann-La Roche AG, Pfizer Inc., Coherus BioSciences Inc., Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited
Get The Full Anti-Vascular Endothelial Growth Factor Therapeutics Market Report:
Which Region Represents The Largest Share Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2025. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Anti-Vascular Endothelial Growth Factor Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market 2026, By The Business Research Company
Anti Vascular Endothelial Growth Factor Therapeutics Market Report 2026
Tumor Necrosis Factor Inhibitor Drugs Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model